Edition:
India

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

4.64USD
22 Nov 2017
Change (% chg)

$0.11 (+2.43%)
Prev Close
$4.53
Open
$4.55
Day's High
$4.70
Day's Low
$4.51
Volume
121,446
Avg. Vol
351,469
52-wk High
$9.25
52-wk Low
$3.95

Chart for

About

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry... (more)

Overall

Beta: 3.23
Market Cap(Mil.): $420.84
Shares Outstanding(Mil.): 80.47
Dividend: --
Yield (%): --

Financials

BRIEF-BioCryst Pharma files for mixed shelf of up to $200 million‍​

* Files for mixed shelf of up to $200 million - SEC filing‍​ Source text: (http://bit.ly/2m4wZHE) Further company coverage:

09 Nov 2017

BRIEF-BioCryst Pharmaceuticals reports Q3 loss per share of $0.18

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

07 Nov 2017

BRIEF-Biocryst’s Rapivab receives FDA approval for a pediatric indication

* Biocryst’s Rapivab (peramivir injection) receives FDA approval for a pediatric indication

21 Sep 2017

BRIEF-Biocryst Pharmaceuticals prices public offering of common stock

* Biocryst Pharmaceuticals prices public offering of common stock

13 Sep 2017

BRIEF-BioCryst Pharmaceuticals announces underwritten public offering​

* BioCryst Pharmaceuticals Inc - ‍offering to sell $80 million of its common stock in an underwritten public offering​

12 Sep 2017

BRIEF-Biocryst announces positive results from mid-stage HAE trial

* Biocryst announces positive results from its Apex-1 Phase 2 trial in HAE

05 Sep 2017

BRIEF-Biocryst Pharmaceuticals Q2 loss per share $0.21

* Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

07 Aug 2017

BRIEF-Deerfield Management Co reports 6.81 pct passive stake in Biocryst Pharmaceuticals

* Deerfield Management Company, L.p reports a 6.81 percent passive stake in Biocryst Pharmaceuticals Inc as of may 25- sec filing Source text for Eikon: Further company coverage:

06 Jun 2017

BRIEF-Biocryst announces Rapivab pediatric SNDA acceptance

* Says snda has a pdufa goal date for a decision by end of september 2017 Source text for Eikon: Further company coverage:

05 Jun 2017

BRIEF-Robert Ingram named chairman of Biocryst Pharmaceuticals

* Robert Ingram named chairman of Biocryst Pharmaceuticals Inc

30 May 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,650 +17.00
Eisai Co., Ltd (4523.T) ¥6,204 -91.00
Roche Holding Ltd. (ROG.S) CHF246.90 +0.10
Roche Holding Ltd. (RO.S) CHF248.20 -0.20
GlaxoSmithKline plc (GSK.L) 1,305.50 +3.00
Shire PLC (SHP.L) 3,735.00 -17.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates